💊 Status Epilepticus Treatment Algorithm Simulator

The First 5 Minutes — Stabilize, Time It, Do Not Wait

Status epilepticus is a time-dependent neurological emergency: the operational definition — a single seizure lasting ≥5 minutes, or recurrent seizures without full recovery of consciousness in between — exists precisely because waiting for the traditional 30-minute threshold delays life-saving treatment. The first actions are identical to any critical resuscitation: airway, breathing, circulation, glucose — performed in parallel with, not instead of, timing the seizure and preparing to treat.

• ≥5 min: Operational definition (continuous or recurrent seizure activity)
• <2 min: ABC assessment target (airway, breathing, circulation)
• <60 mg/dL: Glucose treatment trigger (give thiamine before/with dextrose)
• ~30%: Uncontrolled SE mortality (if seizure activity exceeds 30–60 min)

Why 5 minutes, not 30?

The classical definition of status epilepticus required 30 minutes of continuous seizure activity — a threshold set decades ago, largely because that was thought to be when irreversible neuronal injury began. Clinical and animal data since the 1990s overturned this: most self-terminating seizures stop within 2–3 minutes, so any seizure still going at 5 minutes is statistically unlikely to stop on its own and should be treated as status epilepticus.

The operational (treatment) definition therefore uses two time points: • t1 (~5 min): time at which treatment should be initiated — the seizure is abnormally prolonged • t2 (~30 min for convulsive SE): time at which ongoing seizure activity risks long-term consequences (neuronal injury, network reorganization, pharmacoresistance)

Treating at t1 rather than waiting for t2 is the single biggest driver of improved outcomes in modern status epilepticus care — every additional minute of uncontrolled seizure activity makes the seizure progressively harder to stop, as GABA-A receptors internalize and become less responsive to benzodiazepines while excitatory glutamatergic drive persists.

Benzodiazepine efficacy falls sharply with time: response rates are highest when treatment starts within the first 10 minutes and drop substantially by 30 minutes. "Time is brain" applies to status epilepticus just as it does to acute stroke — every algorithm below is built around not losing minutes.

Primary stabilization and the search for reversible causes

While the seizure clock starts, standard emergency stabilization proceeds simultaneously — not sequentially:

• Airway/breathing: position to protect airway, supplemental oxygen, suction as needed; most convulsive seizures cause transient hypoventilation, but progressive respiratory compromise (especially after benzodiazepine dosing) requires bag-valve-mask or advanced airway management • Circulation: continuous cardiac monitoring, blood pressure, two large-bore IV lines • Point-of-care glucose: hypoglycemia is a rapidly reversible cause of seizures — treat with IV dextrose (D50) if glucose <60 mg/dL; give thiamine first (or concurrently) in patients with possible alcohol use disorder or malnutrition to avoid precipitating Wernicke encephalopathy • Rapid history and exam: prior epilepsy and AED non-adherence, toxic ingestion, fever/infection, recent head trauma, pregnancy status, alcohol/drug withdrawal • Labs sent early: electrolytes (especially sodium, calcium, magnesium), renal/hepatic function, AED levels if applicable, toxicology screen, pregnancy test

This stage ends the moment IV access is secured and the treating team has decided to administer first-line therapy — ideally well before the 5-minute mark, not after it.

First-Line Therapy — Benzodiazepines Delivered Fast, at Full Dose, by Any Route

Benzodiazepines are first-line therapy for status epilepticus because they act quickly by potentiating GABA-A receptor-mediated inhibition, and because — unlike later tiers — they can be given without delay by IV, intramuscular, rectal, or intranasal routes. The single most common reason first-line therapy "fails" is underdosing, not drug choice: clinicians frequently give too little, too slowly, and fail to repeat the dose.

• 0.1 mg/kg: IV lorazepam dose (max 4 mg/dose; may repeat once)
• 10 mg (>40 kg): IM midazolam dose (RAMPART trial — no IV access needed)
• <10 min: Target time-to-treatment (from seizure onset, ideally)
• ~1 in 3: First-line failure rate (seizures persist despite adequate dosing)

Choosing the route and agent

The 2016 American Epilepsy Society guideline, built on randomized evidence including the RAMPART trial, established that route should be chosen by what is fastest to deliver adequately, not by tradition:

• IV lorazepam 0.1 mg/kg (max 4 mg/dose) — preferred when IV access is already in place; may repeat once after 5–10 minutes if seizures continue • IM midazolam 10 mg for patients >40 kg (5 mg for 13–40 kg) — a single fixed dose from an autoinjector; the RAMPART trial found IM midazolam non-inferior to IV lorazepam and, because it avoids the delay of establishing IV access, resulted in seizure cessation before ED arrival more often in prehospital settings • IV diazepam 0.15–0.2 mg/kg (max 10 mg/dose) — reasonable alternative, shorter CNS effect than lorazepam due to redistribution • Rectal diazepam, intranasal or buccal midazolam — used when no IV/IM access is immediately available, particularly in children or home/out-of-hospital settings

Whichever agent is chosen, adequate weight-based dosing is essential: subtherapeutic dosing is common in practice and is the most correctable failure point in the entire algorithm.

RAMPART (NEJM 2012) randomized over 800 patients with prehospital status epilepticus to IM midazolam via autoinjector versus IV lorazepam. IM midazolam was non-inferior — and because paramedics could give it immediately without hunting for a vein in a seizing patient, more patients arrived at the emergency department already seizure-free.

Why benzodiazepine efficacy declines with time

Status epilepticus is, at a receptor level, a moving target. Prolonged seizure activity drives rapid internalization of synaptic GABA-A receptors — the very receptors benzodiazepines potentiate — while NMDA and AMPA glutamate receptors are simultaneously trafficked to the synaptic membrane, increasing excitatory drive. The practical consequence: the same benzodiazepine dose that reliably stops a seizure at 5 minutes becomes progressively less effective at 20, 30, and 45 minutes.

This receptor trafficking is the physiological rationale for the entire time-staged algorithm: instead of repeatedly re-dosing a drug class that is becoming less effective, treatment escalates to a second-line agent with a different mechanism (sodium channel blockade or broader effects) once benzodiazepines have had an adequate trial — typically one full dose and one repeat dose — without full seizure termination.

Second-Line Loading — Fosphenytoin, Valproate, or Levetiracetam

When seizures persist after adequate benzodiazepine dosing, guidelines call for an urgent IV-loaded second-line agent. The landmark ESETT trial (2019) directly compared the three most commonly used options — fosphenytoin, valproate, and levetiracetam — head-to-head and found them statistically equivalent in efficacy and safety, meaning agent selection is now driven mainly by patient comorbidities, allergies, and institutional availability rather than presumed superiority.

• 20 mg PE/kg: Fosphenytoin load (IV, max rate 150 mg PE/min)
• 40 mg/kg: Valproate load (IV; avoid in hepatic failure, pregnancy)
• 60 mg/kg: Levetiracetam load (max 4500 mg; favorable safety profile)
• ~50%: ESETT trial efficacy (seizure cessation, similar across all 3 agents)

The ESETT trial — three agents, one answer

The Established Status Epilepticus Treatment Trial (ESETT, NEJM 2019) was a randomized, blinded, comparative-effectiveness trial in benzodiazepine-refractory status epilepticus, directly comparing fosphenytoin, valproic acid, and levetiracetam. All three arms achieved seizure cessation and improved consciousness in roughly half of patients within 60 minutes, with no significant difference in efficacy or serious adverse events between agents — including hypotension, arrhythmia, and need for intubation.

This result reshaped practice: rather than a strict preference order, second-line selection is now individualized: • Levetiracetam — favored when hepatic disease, pregnancy, or unclear drug interactions are concerns; minimal cardiovascular effect; can be infused relatively quickly • Valproate — effective and fast-acting, but avoided in known or suspected hepatic dysfunction, mitochondrial disease, and generally avoided in pregnancy • Fosphenytoin/phenytoin — long clinical track record, but carries cardiovascular risk (hypotension, arrhythmia) during rapid infusion, requiring cardiac monitoring; interacts with many drugs via CYP metabolism

ESETT randomized 384 patients across three arms and was stopped early for futility of finding a difference — a rare and clinically important result, because it freed clinicians to select the second-line agent based on the individual patient rather than a presumed hierarchy of efficacy.

What "adequate second-line therapy" means before escalating further

Just as with benzodiazepines, an inadequate second-line trial is a common and correctable cause of apparent "refractoriness." A full weight-based loading dose, infused at an appropriate rate, should be completed and given time to work (loading infusions typically run over 10–20 minutes, with peak effect shortly after completion) before concluding the agent has failed.

If seizures persist despite one adequately dosed second-line agent, most protocols proceed directly to refractory-status management rather than sequentially trialing a second and third second-line agent, since each additional non-anesthetic trial burns time without addressing an underlying receptor-level pharmacoresistance that anesthetic-dose therapy is specifically designed to overcome.

Refractory Status Epilepticus — Continuous Infusion, Intubation, and Continuous EEG

Status epilepticus that continues despite an adequately dosed benzodiazepine and an adequately dosed second-line agent is, by definition, refractory status epilepticus — occurring in roughly 40% of status epilepticus cases. Management shifts decisively: from intermittent IV boluses to continuous anesthetic-dose infusion, from ward-level monitoring to ICU admission with airway control, and from clinical seizure observation to continuous EEG, since ongoing electrographic seizures are frequently no longer visible at the bedside once convulsive movements are suppressed.

• 3 main: Continuous infusion agents (midazolam, propofol, pentobarbital)
• Mandatory: Continuous EEG requirement (ongoing electrographic activity often silent clinically)
• Burst-suppression: Typical infusion target (or complete electrographic seizure freedom)
• ~40%: Refractory SE incidence (of all status epilepticus presentations)

Choosing and titrating the continuous infusion

Three anesthetic-dose infusions are most commonly used, each with distinct trade-offs:

• Midazolam infusion — rapid onset, relatively favorable hemodynamic profile, but tachyphylaxis (accumulating tolerance) can develop over days of infusion, sometimes requiring dose escalation or agent switch • Propofol infusion — very rapid onset/offset allowing frequent neurological reassessment, but carries the risk of propofol infusion syndrome (metabolic acidosis, rhabdomyolysis, cardiac failure) with high-dose or prolonged use, requiring close monitoring of triglycerides, creatine kinase, and acid-base status • Pentobarbital (or thiopental) infusion — historically the most reliably effective at achieving burst-suppression, but causes profound hypotension often requiring vasopressor support, prolonged half-life delaying neurological assessment after discontinuation, and immunosuppression with prolonged use

All three require intubation and mechanical ventilation, arterial line and often central venous access, vasopressor availability, and titration guided by continuous EEG rather than a fixed dose — increasing the infusion rate until electrographic seizures stop, or until a burst-suppression pattern is achieved, depending on institutional protocol and clinical severity.

A landmark observation in refractory status epilepticus care: once convulsive movements are pharmacologically suppressed, up to 20% of critically ill patients continue to have ongoing electrographic (non-convulsive) seizures that are completely invisible without EEG — this is why continuous EEG monitoring is considered mandatory, not optional, once continuous infusion begins.

ICU-level supportive care

Refractory status epilepticus management is inseparable from general critical care: mechanical ventilation and sedation-adjusted weaning, hemodynamic support with fluids and vasopressors as needed to counteract anesthetic-induced hypotension, temperature control (fever independently worsens seizure activity and outcome), continued search for and treatment of an underlying etiology (infection, structural lesion, metabolic derangement, toxin, autoimmune process), and prevention of secondary complications — aspiration pneumonia, venous thromboembolism, pressure injury, and critical illness myopathy/neuropathy from prolonged sedation and paralysis.

De-escalation is typically attempted after 24–48 hours of electrographic seizure control, tapering the infusion slowly while watching continuous EEG closely for recurrence — premature or overly rapid weaning is a common cause of apparent relapse into refractory status.

Super-Refractory Status Epilepticus — When Anesthesia Alone Is Not Enough

Super-refractory status epilepticus is defined as status that continues, or recurs on attempted weaning, 24 hours or more after starting anesthetic-dose continuous infusion — including cases that recur while still on adequate anesthetic doses. This population carries the highest morbidity and mortality of the entire algorithm and requires a broadened search for treatable etiologies alongside a widening menu of adjunctive therapies, all guided continuously by EEG.

• ≥24 h: Definition threshold (SE continuing/recurring despite anesthesia)
• NMDA antagonist: Ketamine mechanism (complementary target to GABAergic agents)
• ~10–20%: Autoimmune etiology found (of super-refractory status epilepticus cases)
• 30–50%: Reported mortality (in super-refractory status epilepticus)

Widening the pharmacologic and etiologic search

By the time status epilepticus is super-refractory, GABAergic anesthesia alone has been given a full trial and failed — so effective adjuncts typically target different mechanisms:

• Ketamine infusion — an NMDA-receptor antagonist, mechanistically complementary to GABA-A potentiating anesthetics; particularly rational given that prolonged seizures upregulate NMDA receptor surface expression, meaning ketamine may become relatively more effective the longer status has continued • Magnesium sulfate — considered especially in eclampsia-associated status and some mitochondrial or metabolic etiologies • Ketogenic diet / high-fat enteral therapy — an emerging adjunct with case-series evidence, particularly in prolonged pediatric and adult super-refractory status • Therapeutic hypothermia and electroconvulsive therapy — reported in refractory case series with variable evidence quality, generally reserved for cases failing multiple pharmacologic adjuncts

Equally critical at this stage is an aggressive etiology workup: autoimmune and paraneoplastic encephalitis (anti-NMDA-receptor and other neuronal antibody syndromes) account for a meaningful fraction of super-refractory cases and are specifically treatable with immunotherapy — IV corticosteroids, IVIG, plasma exchange, or rituximab/cyclophosphamide for refractory autoimmune cases — sometimes producing dramatic improvement when identified.

Because a treatable autoimmune or paraneoplastic cause is found in a meaningful minority of super-refractory status epilepticus cases, most protocols recommend early autoimmune/paraneoplastic antibody panels, MRI, and consideration of empiric immunotherapy in cryptogenic super-refractory status — a delayed diagnosis here directly costs recovery potential.

Continuous EEG as the compass for every decision

At every stage from refractory status onward, continuous EEG is not a passive monitor but the primary instrument guiding treatment: it confirms electrographic seizure termination invisible at the bedside, detects recurrence during infusion weaning before convulsions return, quantifies burst-suppression ratio when that is the chosen target, and screens for non-convulsive seizures/status in any patient with unexplained persistent altered consciousness after convulsions have stopped.

Long-term outcome after super-refractory status epilepticus is heavily influenced by etiology (autoimmune and metabolic causes generally carry better prognosis than anoxic or progressive structural causes), duration of uncontrolled seizure activity before adequate treatment, and age/comorbidity — reinforcing, at the far end of the algorithm, the same principle established in the first five minutes: minutes matter, and prompt, adequately dosed, appropriately escalated therapy meaningfully changes outcomes.

Second-line loading agents at a glance